GoTHAM
07 Jun 2021
Trial Summary
GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).
Acronym:
GoTHAM
ACTRN/NCT /ethics:
NCT04261855
Scientific title:
TarGeted THerapy and Avelumab in Merkel Cell Carcinoma 10.17 The GoTHAM Study. A phase Ib/II study of combination avelumab with peptide receptor radionuclide therapy or conventional fractionated radiotherapy in patients with metastatic Merkel cell carcinoma
Sponsor / Cooperative group:
Melanoma and Skin Cancer Trials Limited
Trial & Patient Characteristics
| Cancer Type | Melanoma & other skin |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I, Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2020-10-08 |
| Anticipated End Date | 2024-01-01 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |